April 13, 2013
J.K. WallThe Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity
the school has never seen before.
More
January 21, 2013
J.K. WallThe Indiana Applied Research Enterprise already has received support from John Lechleiter, CEO of Indianapolis-based Eli Lilly
and Co., as a place for collaboration between academic and industrial scientists.
More
December 1, 2012
J.K. WallEarly-stage venture capital has been harder and harder to come by for life sciences companies in recent years, but two Indianapolis
investors are working to raise sizable funds to help fill the gap.
More
November 5, 2012
J.K. WallCommunity Health Network thinks it can help patients, engage doctors and maybe even make some money by trying to turn ideas
within its organization into commercial products, service and companies.
More
October 23, 2012
J.K. WallEli Lilly CEO John Lechleiter on Tuesday called for creation of a "world-class" research institute in Indianapolis to bring
together scientists from universities and corporations to develop new medical therapies and companies.
More
August 6, 2012
J.K. WallEven though the potential payoff for health care innovation is less certain these days, the business case for new ways to
produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural
innovation.
More
July 28, 2012
J.K. WallResearch and development comes under pressure in an age of austerity.
More
February 11, 2012
J.K. WallIn the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies,
an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national
reports on life sciences.
More
January 30, 2012
J.K. WallPurdue University's new Innovation and Commercialization Center is supposed to be a one-stop shop for professors to get help
developing their research into products and for outside investors to find out what research is taking place there.
More
August 13, 2011
Chris O'MalleyLicensed practical nurse Nic Davis invented a device to kill and prevent the introduction of microorganisms that collect at
catheter ports.
More
April 9, 2011
J.K. WallThe Indiana University School of Medicine has licensed a pediatric psychiatrist's patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed
the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
More
April 9, 2011
Chris O'MalleyTechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
More
March 22, 2011
Chris O'MalleyMarcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
More
March 5, 2011
Chris O'MalleyBall State University is conducting a nationwide search for a president to lead a not-for-profit it launched to boost the
commercialization of the university’s intellectual property.
More
January 26, 2011
J.K. WallOver the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center,
launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life
and Health Sciences Quadrangle next to Discovery Park.
More
October 30, 2010
Norm HeikensMark Long was president of the Indiana University Research & Technology Corp., which was responsible for the university’s
tech transfer, before launching a consulting firm, Long Performance Advisors, in 2008.
More
September 18, 2010
Chris O'MalleyIndiana University had a license or two to print money from the commercialization of its technology over the last year—and
did it ever. While Purdue University didn’t collect as much in royalties from commercialization, it pulled down record
levels of research grants.
More
June 19, 2010
Chris O'MalleyA firm that may have developed a breakthrough yeast for ethanol production has landed new investment and high-octane board
members. Two-year-old Xylogenics Inc. also says it plans to license its first bioengineered yeast later this year.
More
June 5, 2010
Chris O'MalleyHaving invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
More
May 29, 2010
Chris O'MalleyFormer collaborator alleges firm breached its agreement with him and refused to pay royalty income.
More
May 15, 2010
Kathleen McLaughlinIndiana University is showing signs that it's finally serious about translating research into commercial product, through
grants it is awarding via its $10 million Innovate Indiana Fund and by developing a computing technology mini-campus.
More
April 28, 2010
J.K. WallPurdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all
for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
More
April 24, 2010
Chris O'MalleyThe upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo
Inc. bring its artery-measurement
product to market as soon as 2011.
More
March 22, 2010
Bloomberg NewsMonday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis
drug Evista and sepsis medicine Xigris.
More
February 18, 2010
IBJ StaffIndianapolis-based Vortek Surgical LLC will relocate to Brownsburg, expanding its headquarters, manufacturing and distribution
operations and creating more than 60 jobs in the next three years.
More
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.